カテゴリ： Allied Market Research, 世界, 医療/バイオ

尿路感染症検査のグローバル市場（2021～2031）：尿道炎、膀胱炎、腎盂腎炎

■ 英語タイトル：Urinary Tract Infection Testing Market By Infection Type (Urethritis, Cystitis, Pyelonephritis), By Test Type (Urinalysis , Urine Cultures, Susceptibility Testing), By End User (Hospitals, Diagnostic Laboratories, Research Institutes), By Test Kit (Home Test Kits, Laboratory Test Kits): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23MC097）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23MC097
■ 発行日：2023年1月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：280
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥535,500見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥859,500見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,440,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[尿路感染症検査のグローバル市場（2021～2031）：尿道炎、膀胱炎、腎盂腎炎]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の調査資料では、2021年には574百万ドルであった世界の尿路感染症検査市場規模が2031年には1,027.4百万ドルへ及び、2022年から2031年の間にCAGR 6.2％増加すると推測されています。本調査資料では、尿路感染症検査の世界市場を広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場概要、感染種類別（尿道炎、膀胱炎、腎盂腎炎）分析、検査種類別（尿検査、尿培養、感受性試験）分析、エンドユーザー別（病院、診断研究所、研究機関）分析、検査キット別（家庭用検査キット、研究所用検査キット）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米/中東・アフリカ）分析、競争状況、企業情報などを整理しました。並びに、本資料に記載されている企業として、Thermo Fisher Scientific, Inc.、Bio-Rad Laboratories、Danaher Corporation、ACON Laboratories Inc.、Cardinal Health Inc.、Stryker Corporation、SYSMEX CORPORATION、Abbott Laboratories、Roche AG、LabCorp(Laboratory Corporation of America Holdings).などが含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の尿路感染症検査市場規模：感染種類別
- 尿道炎の市場規模
- 膀胱炎の市場規模
- 腎盂腎炎の市場規模
・世界の尿路感染症検査市場規模：検査種類別
- 尿検査の市場規模
- 尿培養の市場規模
- 感受性試験の市場規模
・世界の尿路感染症検査市場規模：エンドユーザー別
- 病院における市場規模
- 診断研究所研究機関
- 研究機関研究機関
・世界の尿路感染症検査市場規模：検査キット別
- 家庭用検査キットの市場規模
- 研究所用検査キットの市場規模
・世界の尿路感染症検査市場規模：地域別
- 北米の尿路感染症検査市場規模
- ヨーロッパの尿路感染症検査市場規模
- アジア太平洋の尿路感染症検査市場規模
- 中南米/中東・アフリカの尿路感染症検査市場規模
・競争状況
・企業情報

世界の尿路感染症検査市場は、2022年から2031年まで年平均成長率（CAGR）6.2%で成長するとみられ、2021年の5億7,400万ドルから増加して2031年には10億2,740万ドルに達すると予測されます。

腎臓病や糖尿病などの慢性疾患の有病率の上昇、完全尿分析に対する臨床医の嗜好の高まり、疾患の早期発見に対する需要の急増、院内尿路感染症例の増加、尿分析検査の使用の増加が、尿検査市場の成長を促進する主な要因です。また、低侵襲な尿診断手技に対する需要の増加、高度な尿分析検査手技の採用の増加、新規かつ正確な診断検査の導入に向けた研究開発活動の急増などが、尿路感染症検査市場の成長を支える要因となっています。

尿路感染症検査の世界市場は、尿路感染症治療薬の使用に伴う副作用のため、開発上の課題に見舞われることが予想されます。尿路感染症検査の診断と管理におけるミスの多発は、予測期間中の市場拡大を阻害する可能性があります。尿路感染症に関連する症状が特定できないこと、標準的な診断基準がないこと、サンプルの汚染が多いことなどは、市場拡大の主な障害となっています。

尿路感染症（UTI）は、女性や妊娠中、閉経前後の女性によく見られます。尿路感染症は重篤な罹患率や死亡につながり、罹患者のQOLに影響を及ぼします。抗生物質療法は、症状の持続期間を短縮させる有効な治療法です。耐性菌の発生、抗生物質の好ましくない作用、その他の関連する問題から、尿路結石を管理する代替手段を発見するための研究枠組みが確立されました。

症状を緩和し、健康全般を改善するために、自然療法は多くの病気の治療に広く用いられています。薬草を用いた補完療法は、特別な検討に値する研究テーマです。ある種の尿路結石の管理に薬草療法が有用であることが実証されています。
抗生物質以外の薬物による治療は、尿路結石の発症の可能性を下げ、その症状を軽減するための良い戦略です。天然元素、ミネラル、プロバイオティクスは、関心を集めているいくつかの薬剤の一つです。これらの薬剤はそれぞれ別のメカニズムで作用するため、1回の投与量に薬剤を共配合することで、尿路結石の管理における予防法と治療法の両方に有用な天然製剤を作り出すことができます。

COVID-19のパンデミックはいくつかの不確定要素をもたらし、世界中のさまざまなビジネスが停止し、深刻な経済的損失をもたらしました。COVID-19パンデミックの到来は、製造業やサプライチェーン・物流業界に悪影響を及ぼし、医療ビジネスに悪影響を及ぼしました。政府や医療提供者はCOVID-19のために前代未聞の問題に直面しており、規制環境や手続きにも影響を及ぼしています。COVID-19で入院した患者は尿路感染症と診断されたと報告されています。しかし、複数の検査によって、COVID-19の患者には深刻な尿路症状がないことが明らかになりました。COVID-19患者では、C反応性蛋白やプロカルシトニンといった細菌感染の血中炎症指標が高値であるため、抗生物質が多用されます。しかし、これらの患者の大半は、微生物学的に確認された細菌性重複感染症状を有していました。

本レポートに掲載されている主な企業は、F. Hoffmann-La Roche Ltd、Stryker、Abbott、Siemens、Sysmex Corporation、Cardinal Health、Danaher、Quidel、Bio-Rad Laboratories, Inc.、ACON Labsなどです。

〈ステークホルダーにとっての主なメリット〉
・2021年から2031年までの尿路感染症検査市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、尿路感染症検査市場の市場機会を特定します。
・尿路感染症検査市場に関する2021年から2031年までの市場セグメント、現在の動向、予測、動態を分析し、尿路感染症検査市場の市場機会を明らかにします。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
・尿路感染症検査市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・尿路感染症検査の地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
検査キット別
家庭用検査キット
ラボ用検査キット

感染タイプ別
尿道炎
膀胱炎
腎盂腎炎

検査タイプ別
尿検査
尿培養
感受性検査

エンドユーザー別
病院
診断研究所
研究機関

地域別
・北米
アメリカ
カナダ
メキシコ
・ヨーロッパ
ドイツ
イギリス
フランス
スペイン
イタリア
その他のヨーロッパ
・アジア太平洋
中国
日本
インド
韓国
オーストラリア
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
アラブ首長国連邦
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
Thermo Fisher Scientific, Inc.
Bio-Rad Laboratories
Danaher Corporation
ACON Laboratories Inc.
Cardinal Health Inc.
Stryker Corporation
SYSMEX CORPORATION
Abbott Laboratories
Roche AG
LabCorp(Laboratory Corporation of America Holdings)

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
3.6. Key Regulation Analysis
3.7. Market Share Analysis
3.8. Patent Landscape
3.9. Regulatory Guidelines
3.10. Value Chain Analysis
CHAPTER 4: URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Urethritis
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Cystitis
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Pyelonephritis
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Urinalysis
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Urine Cultures
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Susceptibility Testing
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: URINARY TRACT INFECTION TESTING MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Diagnostic Laboratories
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Research Institutes
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT
7.1. Overview
7.1.1. Market size and forecast
7.2. Home Test Kits
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Laboratory Test Kits
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
CHAPTER 8: URINARY TRACT INFECTION TESTING MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key trends and opportunities
8.2.2. Market size and forecast, by Infection Type
8.2.3. Market size and forecast, by Test Type
8.2.4. Market size and forecast, by End User
8.2.5. Market size and forecast, by Test Kit
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Key market trends, growth factors and opportunities
8.2.6.1.2. Market size and forecast, by Infection Type
8.2.6.1.3. Market size and forecast, by Test Type
8.2.6.1.4. Market size and forecast, by End User
8.2.6.1.5. Market size and forecast, by Test Kit
8.2.6.2. Canada
8.2.6.2.1. Key market trends, growth factors and opportunities
8.2.6.2.2. Market size and forecast, by Infection Type
8.2.6.2.3. Market size and forecast, by Test Type
8.2.6.2.4. Market size and forecast, by End User
8.2.6.2.5. Market size and forecast, by Test Kit
8.2.6.3. Mexico
8.2.6.3.1. Key market trends, growth factors and opportunities
8.2.6.3.2. Market size and forecast, by Infection Type
8.2.6.3.3. Market size and forecast, by Test Type
8.2.6.3.4. Market size and forecast, by End User
8.2.6.3.5. Market size and forecast, by Test Kit
8.3. Europe
8.3.1. Key trends and opportunities
8.3.2. Market size and forecast, by Infection Type
8.3.3. Market size and forecast, by Test Type
8.3.4. Market size and forecast, by End User
8.3.5. Market size and forecast, by Test Kit
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Key market trends, growth factors and opportunities
8.3.6.1.2. Market size and forecast, by Infection Type
8.3.6.1.3. Market size and forecast, by Test Type
8.3.6.1.4. Market size and forecast, by End User
8.3.6.1.5. Market size and forecast, by Test Kit
8.3.6.2. UK
8.3.6.2.1. Key market trends, growth factors and opportunities
8.3.6.2.2. Market size and forecast, by Infection Type
8.3.6.2.3. Market size and forecast, by Test Type
8.3.6.2.4. Market size and forecast, by End User
8.3.6.2.5. Market size and forecast, by Test Kit
8.3.6.3. France
8.3.6.3.1. Key market trends, growth factors and opportunities
8.3.6.3.2. Market size and forecast, by Infection Type
8.3.6.3.3. Market size and forecast, by Test Type
8.3.6.3.4. Market size and forecast, by End User
8.3.6.3.5. Market size and forecast, by Test Kit
8.3.6.4. Spain
8.3.6.4.1. Key market trends, growth factors and opportunities
8.3.6.4.2. Market size and forecast, by Infection Type
8.3.6.4.3. Market size and forecast, by Test Type
8.3.6.4.4. Market size and forecast, by End User
8.3.6.4.5. Market size and forecast, by Test Kit
8.3.6.5. Italy
8.3.6.5.1. Key market trends, growth factors and opportunities
8.3.6.5.2. Market size and forecast, by Infection Type
8.3.6.5.3. Market size and forecast, by Test Type
8.3.6.5.4. Market size and forecast, by End User
8.3.6.5.5. Market size and forecast, by Test Kit
8.3.6.6. Rest of Europe
8.3.6.6.1. Key market trends, growth factors and opportunities
8.3.6.6.2. Market size and forecast, by Infection Type
8.3.6.6.3. Market size and forecast, by Test Type
8.3.6.6.4. Market size and forecast, by End User
8.3.6.6.5. Market size and forecast, by Test Kit
8.4. Asia-Pacific
8.4.1. Key trends and opportunities
8.4.2. Market size and forecast, by Infection Type
8.4.3. Market size and forecast, by Test Type
8.4.4. Market size and forecast, by End User
8.4.5. Market size and forecast, by Test Kit
8.4.6. Market size and forecast, by country
8.4.6.1. China
8.4.6.1.1. Key market trends, growth factors and opportunities
8.4.6.1.2. Market size and forecast, by Infection Type
8.4.6.1.3. Market size and forecast, by Test Type
8.4.6.1.4. Market size and forecast, by End User
8.4.6.1.5. Market size and forecast, by Test Kit
8.4.6.2. Japan
8.4.6.2.1. Key market trends, growth factors and opportunities
8.4.6.2.2. Market size and forecast, by Infection Type
8.4.6.2.3. Market size and forecast, by Test Type
8.4.6.2.4. Market size and forecast, by End User
8.4.6.2.5. Market size and forecast, by Test Kit
8.4.6.3. India
8.4.6.3.1. Key market trends, growth factors and opportunities
8.4.6.3.2. Market size and forecast, by Infection Type
8.4.6.3.3. Market size and forecast, by Test Type
8.4.6.3.4. Market size and forecast, by End User
8.4.6.3.5. Market size and forecast, by Test Kit
8.4.6.4. South Korea
8.4.6.4.1. Key market trends, growth factors and opportunities
8.4.6.4.2. Market size and forecast, by Infection Type
8.4.6.4.3. Market size and forecast, by Test Type
8.4.6.4.4. Market size and forecast, by End User
8.4.6.4.5. Market size and forecast, by Test Kit
8.4.6.5. Australia
8.4.6.5.1. Key market trends, growth factors and opportunities
8.4.6.5.2. Market size and forecast, by Infection Type
8.4.6.5.3. Market size and forecast, by Test Type
8.4.6.5.4. Market size and forecast, by End User
8.4.6.5.5. Market size and forecast, by Test Kit
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Key market trends, growth factors and opportunities
8.4.6.6.2. Market size and forecast, by Infection Type
8.4.6.6.3. Market size and forecast, by Test Type
8.4.6.6.4. Market size and forecast, by End User
8.4.6.6.5. Market size and forecast, by Test Kit
8.5. LAMEA
8.5.1. Key trends and opportunities
8.5.2. Market size and forecast, by Infection Type
8.5.3. Market size and forecast, by Test Type
8.5.4. Market size and forecast, by End User
8.5.5. Market size and forecast, by Test Kit
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Key market trends, growth factors and opportunities
8.5.6.1.2. Market size and forecast, by Infection Type
8.5.6.1.3. Market size and forecast, by Test Type
8.5.6.1.4. Market size and forecast, by End User
8.5.6.1.5. Market size and forecast, by Test Kit
8.5.6.2. Saudi Arabia
8.5.6.2.1. Key market trends, growth factors and opportunities
8.5.6.2.2. Market size and forecast, by Infection Type
8.5.6.2.3. Market size and forecast, by Test Type
8.5.6.2.4. Market size and forecast, by End User
8.5.6.2.5. Market size and forecast, by Test Kit
8.5.6.3. United Arab Emirates
8.5.6.3.1. Key market trends, growth factors and opportunities
8.5.6.3.2. Market size and forecast, by Infection Type
8.5.6.3.3. Market size and forecast, by Test Type
8.5.6.3.4. Market size and forecast, by End User
8.5.6.3.5. Market size and forecast, by Test Kit
8.5.6.4. South Africa
8.5.6.4.1. Key market trends, growth factors and opportunities
8.5.6.4.2. Market size and forecast, by Infection Type
8.5.6.4.3. Market size and forecast, by Test Type
8.5.6.4.4. Market size and forecast, by End User
8.5.6.4.5. Market size and forecast, by Test Kit
8.5.6.5. Rest of LAMEA
8.5.6.5.1. Key market trends, growth factors and opportunities
8.5.6.5.2. Market size and forecast, by Infection Type
8.5.6.5.3. Market size and forecast, by Test Type
8.5.6.5.4. Market size and forecast, by End User
8.5.6.5.5. Market size and forecast, by Test Kit
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2021
CHAPTER 10: COMPANY PROFILES
10.1. Abbott Laboratories
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.2. Roche AG
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.3. Thermo Fisher Scientific, Inc.
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.4. Bio-Rad Laboratories
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.5. Danaher Corporation
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.6. ACON Laboratories Inc.
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.7. Cardinal Health Inc.
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.8. Stryker Corporation
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.9. SYSMEX CORPORATION
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.10. LabCorp(Laboratory Corporation of America Holdings).
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot

LIST OF TABLES
TABLE 01. GLOBAL URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 02. URINARY TRACT INFECTION TESTING MARKET FOR URETHRITIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 03. URINARY TRACT INFECTION TESTING MARKET FOR CYSTITIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 04. URINARY TRACT INFECTION TESTING MARKET FOR PYELONEPHRITIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 05. GLOBAL URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 06. URINARY TRACT INFECTION TESTING MARKET FOR URINALYSIS , BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 07. URINARY TRACT INFECTION TESTING MARKET FOR URINE CULTURES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 08. URINARY TRACT INFECTION TESTING MARKET FOR SUSCEPTIBILITY TESTING, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 09. GLOBAL URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 10. URINARY TRACT INFECTION TESTING MARKET FOR HOSPITALS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 11. URINARY TRACT INFECTION TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 12. URINARY TRACT INFECTION TESTING MARKET FOR RESEARCH INSTITUTES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 13. GLOBAL URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 14. URINARY TRACT INFECTION TESTING MARKET FOR HOME TEST KITS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 15. URINARY TRACT INFECTION TESTING MARKET FOR LABORATORY TEST KITS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 16. URINARY TRACT INFECTION TESTING MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 17. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 18. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 19. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 20. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 21. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 22. U.S. URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 23. U.S. URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 24. U.S. URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 25. U.S. URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 26. CANADA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 27. CANADA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 28. CANADA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 29. CANADA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 30. MEXICO URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 31. MEXICO URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 32. MEXICO URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 33. MEXICO URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 34. EUROPE URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 35. EUROPE URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 36. EUROPE URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 37. EUROPE URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 38. EUROPE URINARY TRACT INFECTION TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 39. GERMANY URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 40. GERMANY URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 41. GERMANY URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 42. GERMANY URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 43. UK URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 44. UK URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 45. UK URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 46. UK URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 47. FRANCE URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 48. FRANCE URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 49. FRANCE URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 50. FRANCE URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 51. SPAIN URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 52. SPAIN URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 53. SPAIN URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 54. SPAIN URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 55. ITALY URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 56. ITALY URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 57. ITALY URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 58. ITALY URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 59. REST OF EUROPE URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 60. REST OF EUROPE URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 61. REST OF EUROPE URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 62. REST OF EUROPE URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 63. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 64. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 65. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 66. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 67. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 68. CHINA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 69. CHINA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 70. CHINA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 71. CHINA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 72. JAPAN URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 73. JAPAN URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 74. JAPAN URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 75. JAPAN URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 76. INDIA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 77. INDIA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 78. INDIA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 79. INDIA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 80. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 81. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 82. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 83. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 84. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 85. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 86. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 87. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 88. REST OF ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 89. REST OF ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 90. REST OF ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 91. REST OF ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 92. LAMEA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 93. LAMEA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 94. LAMEA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 95. LAMEA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 96. LAMEA URINARY TRACT INFECTION TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 97. BRAZIL URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 98. BRAZIL URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 99. BRAZIL URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 100. BRAZIL URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 101. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 102. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 103. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 104. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 105. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 106. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 107. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 108. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 109. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 110. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 111. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 112. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 113. REST OF LAMEA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 114. REST OF LAMEA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 115. REST OF LAMEA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 116. REST OF LAMEA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 117. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 118. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 119. ROCHE AG: KEY EXECUTIVES
TABLE 120. ROCHE AG: COMPANY SNAPSHOT
TABLE 121. THERMO FISHER SCIENTIFIC, INC.: KEY EXECUTIVES
TABLE 122. THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
TABLE 123. BIO-RAD LABORATORIES: KEY EXECUTIVES
TABLE 124. BIO-RAD LABORATORIES: COMPANY SNAPSHOT
TABLE 125. DANAHER CORPORATION: KEY EXECUTIVES
TABLE 126. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 127. ACON LABORATORIES INC.: KEY EXECUTIVES
TABLE 128. ACON LABORATORIES INC.: COMPANY SNAPSHOT
TABLE 129. CARDINAL HEALTH INC.: KEY EXECUTIVES
TABLE 130. CARDINAL HEALTH INC.: COMPANY SNAPSHOT
TABLE 131. STRYKER CORPORATION: KEY EXECUTIVES
TABLE 132. STRYKER CORPORATION: COMPANY SNAPSHOT
TABLE 133. SYSMEX CORPORATION: KEY EXECUTIVES
TABLE 134. SYSMEX CORPORATION: COMPANY SNAPSHOT
TABLE 135. LABCORP(LABORATORY CORPORATION OF AMERICA HOLDINGS).: KEY EXECUTIVES
TABLE 136. LABCORP(LABORATORY CORPORATION OF AMERICA HOLDINGS).: COMPANY SNAPSHOT

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 尿路感染症検査のグローバル市場（2023～2030）：尿道炎、膀胱炎、腎盂腎炎
  • ポイントオブケア（POC）脂質検査のグローバル市場（2021〜2031）：機器、消耗品
  • E型肝炎検査のグローバル市場（2021〜2031）：ELISA HEV IgM検査、ELISA HEV IgG検査、RT-PCR検査
  • 酸素ボンベ＆濃縮器のグローバル市場（2021-2031）：ポータブル型、固定型
  • 単純ヘルペスウイルス治療のグローバル市場（2021-2031）：単純ヘルペスウイルス1型感染症、単純ヘルペスウイルス2型感染症
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23MC097 )"尿路感染症検査のグローバル市場（2021～2031）：尿道炎、膀胱炎、腎盂腎炎" (英文：Urinary Tract Infection Testing Market By Infection Type (Urethritis, Cystitis, Pyelonephritis), By Test Type (Urinalysis , Urine Cultures, Susceptibility Testing), By End User (Hospitals, Diagnostic Laboratories, Research Institutes), By Test Kit (Home Test Kits, Laboratory Test Kits): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。